Research Progress on Antibody-Drug Conjugates Therapy for Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer (NSCLC), recognized as a primary contributor to cancer-related fatalities on a global scale, makes for around 85% of all diagnosed lung cancer instances. Antibody-drug conjugates (ADC), recognized as a cutting-edge approach in cancer therapy, have demonstrated good curative effects in the treatment of numerous malignant cancers in recent years, encompassing NSCLC therapy. These drugs not only increase the patients' survival cycle and remission rate to a certain degree but also lessen harmful side effects and other side effects thanks to their precise guidance feature.They combine the potent damage impact of conventional chemotherapeutic medications with the specific target ability of monoclonal antibodies, overcoming the limitations of those conventional therapeutic approaches, including as targeted therapy, immunotherapy and so on, in terms of drug resistance and cancer progression. With the accumulation of more clinical data and optimization of technology, it gives rise to new expectations pertaining to the therapeutic approach for patients diagnosed with NSCLC, potentially transforming the therapeutic landscape. Next-stage study should focus on optimizing target selection, improving linker technology to enhance stability,and so on,as well as exploring combination strategies with immunotherapy or targeted therapy, thereby promoting the development of individualized therapy.